Nuvalent FY2026 EPS Estimate Reduced by Leerink Partnrs

Nuvalent, Inc. (NASDAQ:NUVL - Free Report) - Research analysts at Leerink Partnrs lowered their FY2026 earnings estimates for shares of Nuvalent in a report released on Tuesday, June 24th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($6.08) per share for the year, down from their prior estimate of ($6.05). The consensus estimate for Nuvalent's current full-year earnings is ($3.86) per share. Leerink Partnrs also issued estimates for Nuvalent's FY2027 earnings at ($4.99) EPS.

Several other equities analysts have also issued reports on NUVL. Leerink Partners lifted their target price on shares of Nuvalent from $125.00 to $140.00 and gave the company an "outperform" rating in a report on Tuesday. UBS Group raised shares of Nuvalent from a "neutral" rating to a "buy" rating and set a $100.00 target price for the company in a report on Friday, March 14th. Robert W. Baird increased their target price on Nuvalent from $105.00 to $112.00 and gave the company an "outperform" rating in a research note on Wednesday. HC Wainwright reiterated a "buy" rating and issued a $130.00 price target (up from $110.00) on shares of Nuvalent in a research note on Tuesday. Finally, Wedbush restated an "outperform" rating and issued a $115.00 target price on shares of Nuvalent in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Nuvalent currently has an average rating of "Moderate Buy" and an average price target of $119.60.

Nuvalent Trading Up 0.1%

NUVL opened at $79.13 on Friday. The company has a market cap of $5.68 billion, a price-to-earnings ratio of -18.03 and a beta of 1.34. The stock has a fifty day simple moving average of $74.57 and a two-hundred day simple moving average of $76.43. Nuvalent has a 12-month low of $55.54 and a 12-month high of $113.51.

Nuvalent (NASDAQ:NUVL - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.14) by ($0.04). During the same period last year, the firm posted ($0.69) EPS.

Institutional Investors Weigh In On Nuvalent

A number of hedge funds have recently made changes to their positions in NUVL. Crowley Wealth Management Inc. acquired a new stake in Nuvalent in the 4th quarter worth approximately $27,000. CWM LLC grew its holdings in Nuvalent by 588.5% during the first quarter. CWM LLC now owns 420 shares of the company's stock worth $30,000 after acquiring an additional 359 shares during the period. ANTIPODES PARTNERS Ltd purchased a new position in Nuvalent during the first quarter valued at approximately $38,000. Quarry LP acquired a new position in Nuvalent in the fourth quarter valued at approximately $39,000. Finally, Covestor Ltd lifted its holdings in Nuvalent by 705.7% in the first quarter. Covestor Ltd now owns 983 shares of the company's stock valued at $70,000 after acquiring an additional 861 shares during the period. 97.26% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Nuvalent

In related news, CEO James Richard Porter sold 27,000 shares of the business's stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $68.94, for a total value of $1,861,380.00. Following the completion of the sale, the chief executive officer now owns 249,062 shares in the company, valued at approximately $17,170,334.28. The trade was a 9.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 10.20% of the stock is currently owned by insiders.

About Nuvalent

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.